n the past 10 years, percutaneous transluminal angioplasty and coronary artery bypass graft surgery has become the main strategies in the treatment of ischemic heart disease, and the results have improved remarkably. However, diffuse coronary stenoses or microangiopathic disease still represent a difficulty in using these strategies as treatment, and thus medical therapy is often selected. For the treatment of these ungraftable lesions, promoting angiogenesis may help increase coronary collateral blood flow and alleviate the ischemic episode. For this purpose, angiogenic factors such as fibroblast growth factor family proteins, 1 hepatocyte growth factor 2 or a vascular endothelial growth factor 3,4 may be useful. The selective injection of replication-defective adenovirus vector into the target organ to express a specific protein is a promising strategy for the treatment of ischemic heart disease with ungraftable arteries. Recently, the intracoronary injection of a recombinant adenovirus expressing human fibroblast growth factor (FGF)-5 resulted in an improvement of regional wall motion abnormalities and blood flow in an epicardial coronary stenosis model in pigs during pacing-induced stress. 5 The improvement in collateral flow has been demonstrated, but the effect of a recombinant adenovirus expressing the human-secreted form of FGF-2 on the microembolized heart has not been clarified. Furthermore, assessing the time course of left ventricular function by serial echocardiographic examination has not been performed, nor has the quantitative assessment of myocardial collateral blood flow in a microembolized model. Thus, in the present study, collateral development was assessed by microsphere methods and by the histological assessment of angiogenesis in a rabbit model.
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Methods

Preparation of Adenoviral Vector
Adenoviral vector was prepared as described previously. [6] [7] [8] Recombinant cDNA for the secreted form of human FGF-2 was constructed by the addition of the signal sequence of FGF-4 encoding 22 amino acids to the 5' end of the cDNA of human full-length FGF-2 coding 155 amino acids (provided by T. Maciag). 9 Replication-defective E1 and E3 adenoviral vectors were prepared as described previously. Briefly, secreted FGF-2 (sFGF-2) cDNA was placed into a cassette cosmid vector under a CA promoter comprising a cytomegalovirus enhancer and chicken -actin promoter (pAdCAsFGF-2). A recombinant adenovirus was constructed by in vitro homologous recombination in 293 cells using pAdCAsFGF-2 and the adenovirus DNA-terminal protein complex. The desired recombinant adenovirus, designated AdCAsFGF-2, was purified by ultracentrifugation through a CsCl2 gradient followed by extensive dialysis. Contamination by the wild-type adenovirus was excluded by 
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the polymerase chain reaction designed for E1 amplification. The titer of the virus stock was assessed by a plaque-formation assay using the 293 cells and expressed in plaque formation units (PFU). We also used the control adenoviruses, AdCAlacZ, expressing bacterial -galactosidase, and Ad1w, which did not contain any exogenous gene to be expressed.
Intracoronary Infusion of Adenovirus
Japanese White rabbits (3.0-3.7 kg) were anesthetized with pentobarbital sodium (30 mg/kg) injected into the ear vein, intubated and ventilated (tidal volume 30 ml; frequency, 30 breaths/min) with a Harvard rodent ventilator (model 683). The right carotid artery was exposed in a sterilized manner and cannulated with a 5Fr balloon catheter (Create-Medics Co, Kanagawa, Japan). The tip of the catheter was located at the sinus of Valsalva, and the aortic pressure was measured through the catheter connected to the fluid-filled transducer. The catheter position was confirmed by fluoroscopy (Siemens, Germany), and the balloon was inflated for 30 s in the ascending aorta. During the balloon inflation, the rabbits (n=8) received saline with an injection of 1.1×10 5 microspheres (MS; diameter: 25 m; NEM-003, NEN TM ). The adenovirus infusion was conducted simultaneously with the microembolization by mixing the microspheres and the adenovirus. Animals in the LacZ group (n=6) received 2×10 9 PFU Ad1w (n=1) or AdCAlacZ (n=5) with an injection of 1.1×10 5 MS. Animals of the FGF group (n=9) received 2×10 9 PFU AdCAsFGF-2 with an injection of 1.1×10 5 MS. The catheter was flushed with 5 ml saline before the balloon was deflated. Each rabbit was given 100 mg ampicillin subcutaneously. The care of the animals and the protocol were in accordance with guidelines of the Animal Ethics Committee of Yamaguchi University School of Medicine.
Evaluation of Cardiac Performance
To evaluate left ventricular (LV) function, parasternal long axis 2-dimensional echocardiography was performed with a 7.5-MHz transducer (model SSD-630, Aloka, Japan). A 2-dimensionally guided M-mode echo was recorded on a strip chart before and after the MS injection, and at 1, 3, 7, and 14 days after the MS injection. The LV end-diastolic diameter (LVEDD) was identified at the R wave of the ECG, and the end-systolic diameter (LVESD) was at the maximum inward excursion of the posterior wall. The fractional shortening (FS) expressed as a percentage was determined as (LVEDD -LVESD) / LVEDD × 100. Two weeks after the surgery, the animals were anesthetized with intravenous pentobarbital and intubated through a tracheotomy. A 2Fr micromanometer-tipped catheter (Millar Instruments, Model SPC-320, TX, USA) was inserted into the left ventricle via the carotid artery. A 4Fr catheter was inserted into the descending aorta via the femoral artery. Aortic and LV pressures were digitized with a microcomputer equipped with an A/D converting board (DT7102, Data Translation). Heart rate (HR), peak LV systolic pressure (PLVP), LV enddiastolic pressure (LVEDP), maximal rates of LV pressure rise (+dP/dt), and maximal rates of LV pressure fall (-dP/dt) were calculated. After a left thoracotomy through the fifth intercostal space, a snare occluder was placed around the proximal left anterior descending coronary artery. A catheter was inserted into the left atrium from the left atrial appendage for the administration of colored-microspheres (1.2 million each, DYE-TRACK, TRITON Co) in order to measure myocardial blood flow before and after the occlusion of the left anterior descending artery. Reference blood was withdrawn through the aortic catheter at a rate of 2 ml/min, beginning 10 s before the injection of the colored microspheres and lasting for 90 s. Then Trypan blue dye was injected into the left atrium to delineate the area at risk for ischemia. After killing the animal with a potassium chloride injection, the heart was immediately excised and washed in cold saline, and the left ventricle was sliced transversely into 5 mm sections. Samples were cut into pieces from the risk area and non-risk area as indicated by Trypan blue dye.
Histochemical Analysis
A transverse slice of the left ventricle was immediately fixed in phosphate buffered saline (PBS) containing 2% formaldehyde and 0.2% glutaraldehyde (pH 7.4) for at least 12 h at 4°C. The sections were incubated with a solution containing 5 mmol/L K3[Fe(CN)6], 5 mmol/L K4[Fe(CN)6], 1 mmol/L MgCl2 and 1.0 mg/ml 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-Gal, Sigma) in PBS at 37°C for 6 h. After the X-Gal staining, sections were re-fixed, embedded in paraffin, sectioned at 4 m, and counterstained with hematoxylin -eosin for microscopic examination.
Tissue Digestion and Microsphere Recovery by Filtration
The heart and blood samples were individually digested in tubes with 4 ml of 16 mol/L KOH and 1 ml of 0.2% Tween 80. The digested tissue pieces were individually filtered through 10-m-pore polycarbonate filters (Millipore filter TM ) by use of a negative pressure. To extract the dye from the microspheres, 100-300 l of dimethylformamide were added to each tube and the tubes were vigorously vortexed. The samples were centrifuged (1,500 G, 3 min), and the absorbance of each supernatant was determined with a spectrophotometer (U-2000A, HITACHI) (wave length range, 300-820 nm).
Calculation of Myocardial Blood Flow
The myocardial blood flow (Qs) was calculated by the following equation: Qs = As (Qr / Ar) where Qr represents the withdrawal rate of the reference blood, and Ar and As represent the absorbance units in the reference blood and sample tissue, respectively. The blood flow rate was divided by the tissue weight to obtain a flow rate per unit of tissue. 10, 11 
Immunohistochemistry
Before immunostaining, the paraffin-embedded sections were dewaxed and hydrated. The sections were stained with mouse monoclonal antibody to CD31 (JC/70A, DAKO) using a labeled streptavidin-biotin (LSAB) method. The monoclonal antibody was used at a dilution of 1:10. The specificity of the antibody was confirmed previously. 12 After being washed in PBS 3 times, the sections were incubated with biotin-rabbit anti-mouse antibody (1:200 dilution; Zymed) for 3 h. The tissue sections were counterstained with hematoxylin. The protein expression of basic FGF (bFGF) was detected by immunostaining with mouse monoclonal antibody specific for human bFGF (Wako Pure chemical Industries, Japan) using a LSAB Kit. The monoclonal antibody was used at a dilution of 1:100.
Vascular Density
Five unit areas (0.25×0.25 mm 2 ) were randomly chosen from each preparation, and the number of arterioles and capillaries were counted in each unit area. Azan stain was used for capillary counting, and anti-CD31 immunostaining with hematoxylin staining was used for counting arterioles by 2 examiners without knowledge of which treatment a given animal had received. The number of vessels in 5 unit areas were averaged. Interobserver variability was <5%.
Statistical Analysis
Data were expressed as mean ± SEM. A comparison among the 3 groups was performed with one-way ANOVA for the vascular density, coronary blood flow, and hemodynamic parameters at 14 days. When a significant difference was detected, multiple-comparison was done using Scheffé's test between the groups. A comparison between preembolization and post-embolization was performed with paired t test for hemodynamic parameters. The repeated measure of ANOVA was done for the serial changes in the fractional shortening. Post hoc multiple comparisons were done by Scheffé's test. P<0.05 was considered to be significant.
Results
Amelioration of Myocardial Dysfunction
M-mode echocardiography of the LV was performed without any knowledge of which treatment a given animal had received. With microembolization, %FS decreased from 46±2% to 27±1% in the FGF group, 44±1% to 27±1% in the saline group, and 42±1% to 25±2% in the LacZ group. In AdCAsFGF-2-treated animals at 3 days after microembolization, %FS had significantly recovered from the value it had reached at 30 min after microembolization (Fig 2) . At 14 days, %FS improved to 41±1% in the FGF group compared with 31±1% in the saline group (p<0.01; FGF group vs saline group) and 32±1% in the LacZ group (p<0.01; FGF group vs LacZ group) (Figs 1, 2) . 
Effects of Gene Transfer of AdCAsFGF-2 on Hemodynamics
As shown in Table 1 , the values of heart rate, mean aortic pressure, LV peak pressure, and ±dP/dt were significantly decreased with microembolization compared with those before microembolization. Injection with AdlacZ and AdCAsFGF-2 did not alter heart rate, LV peak pressure or mean aortic pressure in comparison with the saline group at 14 days. However, the values of LVEDP were significantly lower in hearts injected with AdCAsFGF-2 than in the LacZ group. Furthermore, the values of ±dP/dt were significantly higher in hearts injected with AdCAsFGF-2 than in the LacZ group injected with AdlacZ, and there was a trend toward an increase in ±dP/dt in hearts injected with AdCAsFGF-2 in comparison with the saline group.
Gene Transfer and bFGF Expression in Left Ventricular Sections
Hearts were examined using histochemical staining in order to evaluate the microscopic distribution of transgene expression. Histochemical staining of a left ventricular cross section from hearts injected with AdlacZ (day 14) revealed -gal activity in the myocardium (Fig 3E,F) . To evaluate whether other tissues were infected, we histologically examined sections of aorta, kidney and skeletal muscle following injection with AdlacZ. There was no histological evidence of -gal activity in these organs. Human bFGF protein was expressed more in the FGF group (Fig 3C) than in the saline (Fig 3A) or LacZ groups (Fig 3B) or in the sections of the FGF group incubated with PBS containing no primary antibody, which served as the negative control (Fig 3D) .
Histological Assessment of Collaterals
The arteriole density of LV myocardium at 14 days was markedly increased in the FGF group (83.2±3.2 /mm 2 ) (Fig 4F) compared with the saline (35.2±3.2 /mm 2 , p<0.01 vs FGF group) (Fig 4D) and LacZ groups (28.8±3.2 /mm 2 , p<0.01 vs FGF group) (Figs 4E, 5A) . The capillary density of the LV myocardium was significantly increased in the FGF group (2369.5±51.2 /mm 2 ) (Fig 4C) compared with the saline (1708.8±120.0 /mm 2 ; p<0.01 vs FGF group) (Fig 4A) and LacZ groups (1763.2±51.2 /mm 2 ; p<0.05 vs FGF group) (Figs 4B, 5B). There was no significant difference between the saline and the LacZ group (Fig 5B) .
Collateral Blood Flow
In the risk area (mean risk area was 44.3±11.6% of LV (Fig 6A) . In the non-risk area, there were no significant differences in myocardial collateral blood flow among the 3 groups (Fig 6B) .
Discussion
The purpose of the present study was to evaluate the efficacy of transcoronary gene transfer of the secreted form of FGF-2 on the development of collaterals in a microembolized ischemic model in the rabbit heart. Basic FGF has a potent angiogenic effect, and its application in in vitro 13 and in vivo studies has demonstrated an acceleration of the development of collateral vessels. 1, 4, [14] [15] [16] [17] [18] [19] [20] [21] Giordano et al showed the efficacy of FGF-5 transfer in a pig ischemic model for the sake of attenuating pacing-induced myocardial ischemia. 5 In that study, an ameroid constrictor was placed around the proximal left circumflex coronary artery to effect the complete closure of the artery. However, the efficacy of bFGF transfer in microembolized models has not been clarified. In the present study, we utilized a microembolized model in the rabbit heart with 25-m microspheres. This model showed LV dysfunction as confirmed by serial echocardiographic observations. In both the saline and LacZ groups, the recovery of LV systolic function was slow, and at 2 weeks after the microembolization the recovery was approximately 30% of the basal level. Application of the secreted form of FGF-2 improved %FS at 2 weeks after microembolization, which demonstrates the efficacy of FGF-2 transfer to facilitate recovery from contractile dysfunction in the microembolized model. In recent years, several groups have proposed indications for the use of FGF to improve blood flow in the presence of tissue ischemia in animal experiments. 1, 4, [14] [15] [16] [17] [18] [19] [20] [21] To maintain the expression of angiogenic factors in the myocardium, an adenovirus vector has been used because of its high efficiency for gene transfer in comparison with liposome or other virus vectors. 5, [22] [23] [24] Barr et al demonstrated that catheter-mediated infusion of replication-defective adenovirus into the coronary circulation was an efficient method for inducing recombinant gene expression in both coronary arteries and in the myocardium for at least 2 weeks. 22 In the present study, a single intracoronary infusion of 2×10 9 PFU of adenovirus vector resulted in recombinant gene expression in the myocardium for 2 weeks, as demonstrated by LacZ expression and human bFGF expression in the myocardium.
In a microembolized model, Battler et al showed that bFGF accelerated angiogenesis in the myocardium. 25 In their study, the left anterior descending coronary artery was microembolized with beads containing bFGF, but an evaluation of myocardial blood flow was not performed. In the present study, the physiological significance of collateral circulation development was assessed by measuring coronary collateral flow with the microsphere method. We demonstrated an increase in collateral blood flow in the FGF-2 gene transfer group as compared with the other groups. Furthermore, we confirmed the angiogenesis histologically. The capillary and arteriolar density were significantly increased at 2 weeks after the transfer of FGF-2 in comparison with the saline or LacZ groups.
Thus, this study demonstrated that the in vivo gene transfer of the secreted form of FGF-2 using replicationdefective adenovirus vector through the coronary artery is effective for the recovery of LV dysfunction and for the development of collateral vessels in microembolized rabbit hearts.
Study Limitation
The proinflammatory effect of the adenovirus vector is known and may hinder the use of adenovirus vector in clinical applications. The recently developed adeno-associated vector has less proinflammatory effect and may be useful. The immune-response to the adenovirus vector limits the duration of gene expression to 2-3 weeks, after which the vector could be eliminated by the immune response. However, gene expression for 2-3 weeks may be enough to promote collateral vessels formation.
Conclusion
Transcoronary gene transfer of bFGF effectively attenuated LV dysfunction by facilitating collateral vessel development in the microembolized rabbit heart.
